RBC Capital analyst Michael Dahl maintained a Sell rating on DR Horton (DHI – Research Report) yesterday and set a price target of $142.00. The company’s shares closed yesterday at $143.13.
Dahl covers the Consumer Cyclical sector, focusing on stocks such as DR Horton, Lennar, and Mohawk. According to TipRanks, Dahl has an average return of 5.4% and a 57.49% success rate on recommended stocks.
In addition to RBC Capital, DR Horton also received a Sell from Goldman Sachs’s Susan Maklari in a report issued yesterday. However, today, Citi maintained a Buy rating on DR Horton (NYSE: DHI).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $157.93 and a one-year low of $88.46. Currently, DR Horton has an average volume of 2.68M.
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHI in relation to earlier this year. Most recently, in November 2023, Barbara K. Allen, a Director at DHI sold 470.00 shares for a total of $59,318.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DR Horton (DHI) Company Description:
Founded in 1978, Texas-based D.R. Horton, Inc. is a homebuilding company that is engaged in the construction and sale of single-family homes through its diverse brand portfolio that includes D.R. Horton, Emerald Homes, Express Homes and Freedom Homes.
Read More on DHI:
